Targeted drug shows promise for Hard-to-Treat lymphoma
NCT ID NCT05068440
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug zanubrutinib in 65 adults with a specific genetic form (CD79B mutant) of relapsed or refractory diffuse large B-cell lymphoma, an aggressive blood cancer. Participants took zanubrutinib capsules twice daily and were monitored for tumor response and side effects. The goal was to see if this targeted therapy could shrink or control the cancer when standard treatments have failed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib (a targeted cancer drug taken as capsules)
What this could lead to
If successful, this could provide a new treatment option for people with a specific genetic subtype of aggressive lymphoma that has not responded to standard therapy.
What could go wrong
This is a small, single-arm Phase 2 study with no comparison group, so results may not be definitive. The drug may not work for all patients and could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital
Hefei, Anhui, 230088, China
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, 100050, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Guangdong Provincial Peoples Hospital Huifu Branch
Guangzhou, Guangdong, 510120, China
-
Hainan Cancer Hospital
Haikou, Hainan, 570312, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Institute of Hematology and Hospital of Blood Disease
Tianjin, Tianjin Municipality, 300020, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042, China
-
Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030013, China
-
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
Taizhou Hospital of Zhejiang
Taizhou, Zhejiang, 317000, China
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510120, China
-
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, 330006, China
-
The First Affiliated Hospital of Shantou University Medical College
Shantou, Guangdong, 515041, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
-
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
-
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Yunnan Cancer Hospital
Kunming, Yunnan, 650100, China
-
Zhejiang University College of Medicine Second Affiliated Hospital
Hangzhou, Zhejiang, 310009, China